We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+28.11%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$1.82B
AUM Growth
+$1.6B
Cap. Flow
+$16.1M
Cap. Flow %
0.88%
Top 10 Hldgs %
91.96%
Holding
76
New
25
Increased
14
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$8.59M
2
ESPR
Esperion Therapeutics
ESPR
+$7.67M
3
MDT icon
Medtronic
MDT
+$7.27M
4
ICUI icon
ICU Medical
ICUI
+$7.06M
5
EHC icon
Encompass Health
EHC
+$5.8M

Top Sells

Rank Stock Value
1
HOLX
Hologic
HOLX
+$19.2M
2
PFE icon
Pfizer
PFE
+$16.7M
3
SNY icon
Sanofi
SNY
+$15.1M
4
SIBN icon
SI-BONE Inc
SIBN
+$9.12M
5
CI icon
Cigna
CI
+$6.7M

Sector Composition

Rank Sector Weight
1 Healthcare 11.6%
2 Industrials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
26
Insmed
INSM
$21.4B
$3.86M 0.21%
140,184
+65,819
+89% +$1.56M
BSX icon
27
Boston Scientific
BSX
$71.1B
$3.73M 0.2%
+106,338
New +$3.83M
CALT
28
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$3.72M 0.2%
+160,218
New +$3.17M
BAX icon
29
Baxter International
BAX
$14.7B
$3.65M 0.2%
+42,439
New +$3.7M
SYNH
30
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$3.18M 0.17%
+54,577
New +$2.93M
MTEM
31
DELISTED
Molecular Templates, Inc.
MTEM
$3.17M 0.17%
+15,321
New +$3.56M
ACRS icon
32
Aclaris Therapeutics
ACRS
$835M
$2.8M 0.15%
1,728,787
-890,400
-34% -$1.19M
HAE icon
33
Haemonetics
HAE
$3.88B
$2.59M 0.14%
+28,937
New +$2.92M
MCK icon
34
McKesson
MCK
$97.2B
$2.45M 0.13%
15,942
-20,454
-56% -$2.95M
MBIO icon
35
Mustang Bio
MBIO
$4.5M
$2.44M 0.13%
+1,025
New +$2.4M
UHS icon
36
Universal Health Services
UHS
$10.2B
$2.25M 0.12%
+24,178
New +$2.42M
IQV icon
37
IQVIA
IQV
$37.6B
$2.24M 0.12%
15,773
+7,441
+89% +$1.01M
BMY icon
38
Bristol-Myers Squibb
BMY
$135B
$2.12M 0.12%
36,109
-100,816
-74% -$6.03M
FATE icon
39
Fate Therapeutics
FATE
$300M
$2.09M 0.11%
60,892
+20,160
+49% +$601K
PRNB
40
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$1.82M 0.1%
30,395
+21,468
+240% +$1.33M
BIO icon
41
Bio-Rad Laboratories Class A
BIO
$8.91B
$1.58M 0.09%
+3,505
New +$1.55M
XRAY icon
42
Dentsply Sirona
XRAY
$2.86B
$1.54M 0.08%
35,059
-17,586
-33% -$744K
BDX icon
43
Becton Dickinson
BDX
$46.9B
$1.46M 0.08%
6,232
-25,543
-80% -$6.16M
FPRX
44
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.45M 0.08%
+237,174
New +$977K
STRO icon
45
Sutro Biopharma
STRO
$425M
$1.21M 0.07%
+15,601
New +$1.5M
AHCO icon
46
AdaptHealth
AHCO
$912M
$1.14M 0.06%
71,000
-149,896
-68% -$2.51M
PTCT icon
47
PTC Therapeutics
PTCT
$5.77B
$998K 0.05%
+19,677
New +$967K
ZGNX
48
DELISTED
Zogenix, Inc.
ZGNX
$799K 0.04%
29,575
-29,212
-50% -$806K
TCRR
49
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$591K 0.03%
+38,494
New +$444K
PODD icon
50
Insulet
PODD
$11.6B
$479K 0.03%
+2,465
New +$471K
1
2
3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Endurant Capital Management held 76 positions worth $1.82B, up 727% from $221M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Endurant Capital Management's Q2 2020 filing shows 25 new, 14 increased, 16 reduced and 20 closed positions. Its largest new stake was Esperion Therapeutics: 183,249 shares worth $9.4M. The largest sale was Hologic, an estimated $19.2M.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, down from 90% a quarter earlier, followed by Industrials.

  • Endurant Capital Management's largest Q2 2020 buy was Esperion Therapeutics: 183,249 shares worth $9.4M.
  • Endurant Capital Management added most to Centene in Q2 2020, an estimated $8.59M increase.
  • Endurant Capital Management's biggest Q2 2020 reduction was Hologic, cutting an estimated $19.2M.
  • Endurant Capital Management fully exited Pfizer in Q2 2020, selling an estimated $16.7M.
  • Endurant Capital Management's ten largest holdings make up 92% of its $1.82B portfolio in Q2 2020.
  • Endurant Capital Management opened 25 new positions and closed 20 in Q2 2020.
  • Endurant Capital Management's portfolio value rose 727% quarter-over-quarter to $1.82B.

Based on Endurant Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.